Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Small Molecule Inhibitors of the Artemis Endonuclease and Thiadiazines as HSP70 Agonists

Terrab, Leila (2021) Small Molecule Inhibitors of the Artemis Endonuclease and Thiadiazines as HSP70 Agonists. Doctoral Dissertation, University of Pittsburgh. (Unpublished)

PDF (ETD file)
Primary Text

Download (6MB) | Preview
PDF (Spectra files)
Supplemental Material

Download (25MB) | Preview


The first chapter of this dissertation covers the analog synthesis of three screening hit compounds previously identified as Artemis inhibitors. Artemis is a metalloenzyme nuclease involved in the nonhomologous end-joining pathway, a DNA damage repair pathway. The screening hits included the hydroxamic-acid containing Droxinostat, a 2-amino-3-carboxythiophene, and a 2-aminothiazole. Previous work by our group identified chromane analogs of Droxinostat to show Artemis inhibition, and this work mostly focuses on exploring new substitution patterns of the chromane scaffold for our structure-activity relationship (SAR) studies. While a few of the chromane analogs inhibited Artemis, they have also been shown to target histone deacetylases (HDACs), another family of metalloenzymes. None of the 2-amino-3-carboxythiophene nor 2-aminothiazole analogs have shown Artemis inhibition. The Artemis crystal structure has only become available in February 2020, and our group used an Artemis homology model and SAR studies to guide our compound design.

The second chapter covers the selective functionalization of the 1,2,6-thiadiazine 1,1-dioxide scaffold for the synthesis of medicinally relevant compounds. We employed chemoselective transformations of the thiadiazine’s sulfamide nitrogens and vinylogous carbamate. We were interested in using the sulfamide group as a bioisosteric replacement to the urea substructure of MAL1-271, an HSP70 agonist. HSP70 proteins are ATP-dependent molecular chaperones that regulate protein folding, and HSP70 modulation has shown a therapeutic potential in neurodegenerative diseases, such as Huntington’s Disease. Our collaborators evaluated our compounds in a Huntington Disease model, where their ability to reduce polyglutamine (polyQ) aggregates was assayed. A few analogs have shown higher efficacy than MAL1-271. We also decided to utilize our method for the synthesis of thiadiazine-containing HDAC6 inhibitors; however, our assays did not show a promising HDAC inhibition profile.


Social Networking:
Share |


Item Type: University of Pittsburgh ETD
Status: Unpublished
CreatorsEmailPitt UsernameORCID
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee MemberDeiters,
Committee MemberKoide,
Committee MemberHuryn,
Committee ChairWipf,
Date: 3 May 2021
Date Type: Publication
Defense Date: 11 December 2020
Approval Date: 3 May 2021
Submission Date: 3 February 2021
Access Restriction: 1 year -- Restrict access to University of Pittsburgh for a period of 1 year.
Number of Pages: 274
Institution: University of Pittsburgh
Schools and Programs: Dietrich School of Arts and Sciences > Chemistry
Degree: PhD - Doctor of Philosophy
Thesis Type: Doctoral Dissertation
Refereed: Yes
Uncontrolled Keywords: Artemis Endonuclease HSP70 Thiadiazines
Date Deposited: 03 May 2022 05:00
Last Modified: 19 May 2023 14:04


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item